Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML

@article{Tefferi2009DetectionOM,
  title={Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML},
  author={Ayalew Tefferi and K Lim and O. A. L. Abdel-Wahab and Terra L. Lasho and Jay Patel and Mrinal S Patnaik and Curtis A. Hanson and Animesh Pardanani and Dwight Gary Gilliland and Ross L. Levine},
  journal={Leukemia},
  year={2009},
  volume={23},
  pages={1343-1345}
}
lated in ALL are calcitonin, ER, p15, p16, HIC-1, p73, E-cadherin, promoter-associated CpG islands, Wnt and Src among others. In proliferating cells, DNA methylation is critically dependent on continued expression of DNA methyltransferases. Moreover, several groups have recently shown that aberrant DNA methylation is an independent prognostic factor for disease-free survival, overall survival and treatment resistance. The cytosine analogue 5-aza-20-deoxyazacytidine 20-deoxy5-azacytidine… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 118 extracted citations

Updates in cytogenetics and molecular markers in MDS.

Current hematologic malignancy reports • 2011
View 14 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-6 of 6 references

TET2 is a novel tumor suppressor gene inactivated in myeloproliferative neoplasms: identification of a Pre-JAK2 V617F event

F Delhommeau, S Dupont, +3 authors VD Valle
ASH Annual Meeting Abstracts • 2008

World Health Organization Classification of Tumours of Hematopoietic and Lymphoid Tissues

ES Jaffe, NL Harris, H Stein, JW. Vardiman
IARC Press: Lyon, France, • 2001

Similar Papers

Loading similar papers…